Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18, with chronic genotype 1 HCV infection~* HCV treatment-naive~* HCV RNA \> 10,000 IU/mL at screening~* Cirrhosis determination; a liver biopsy may be required~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Co-infection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 weeks (Type: EXPERIMENTAL): LDV/SOF administered for 12 weeks
- LDV/SOF+RBV 12 weeks (Type: EXPERIMENTAL): LDV/SOF+RBV administered for 12 weeks.
- LDV/SOF 24 weeks (Type: EXPERIMENTAL): LDV/SOF administered for 24 weeks
- LDV/SOF+RBV 24 weeks (Type: EXPERIMENTAL): LDV/SOF+RBV administered for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).